Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Hodgkin Disease

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Hematologic Diseases

Myeloid Leukemia

Acute Myeloid Leukemia

Lymphosarcoma

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Acute Non Lymphoblastic Leukemia

Hodgkin Lymphoma

Acute Graft Versus Host Disease

Non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01

Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)

non intervational

Shai Yarkoni, MD

Tsila Zuckerman, MD

This is a non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01. Up to 12 subjects who completed ApoGraft-01 study will be offered to participate in this follow-up study.

Subjects who completed ApoGraft-01 study and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend in-clinic visits up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence), physical examination, safety laboratory and concomitant medication use.

Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study

A Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study

GVHD will be assessed according to NIH criteria 2005; current and maximal score at each visit.

Cellect Biotechnology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study	NCT03260101	Acute Myelogeno... Acute Lymphobla... Non Hodgkin Lym... Hodgkin Lymphom...	non intervation...	18 Years - 70 Years	Cellect Biotechnology
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study	NCT03260101	Acute Myelogeno... Acute Lymphobla... Non Hodgkin Lym... Hodgkin Lymphom...	non intervation...	18 Years - 70 Years	Cellect Biotechnology
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study	NCT03260101	Acute Myelogeno... Acute Lymphobla... Non Hodgkin Lym... Hodgkin Lymphom...	non intervation...	18 Years - 70 Years	Cellect Biotechnology

Spots Global Cancer Trial Database for non intervational